Asset Details
Do you wish to reserve the book?
Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials
Do you wish to request the book?
Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials
2019
Overview
The spinocerebellar ataxias (SCAs) are a group of neurodegenerative disorders inherited in an autosomal dominant fashion. The SCAs result in progressive gait imbalance, incoordination of the limbs, speech changes, and oculomotor dysfunction, among other symptoms. Over the past few decades, significant strides have been made in understanding the pathogenic mechanisms underlying these diseases. Although multiple efforts using a combination of genetics and pharmacology with small molecules have been made towards developing new therapeutics, no FDA approved treatment currently exists. In this review, we focus on SCA1, a common SCA subtype, in which some of the greatest advances have been made in understanding disease biology, and consequently potential therapeutic targets. Understanding of the underlying basic biology and targets of therapy in SCA1 is likely to give insight into treatment strategies in other SCAs. The diversity of the biology in the SCAs, and insight from SCA1 suggests, however, that both shared treatment strategies and specific approaches tailored to treat distinct genetic causes of SCA are likely needed for this group of devastating neurological disorders.
Publisher
Elsevier Inc,Elsevier BV,Springer International Publishing,Springer Nature B.V
Subject
/ Ataxin
/ Ataxin-1
/ Ataxin-1 - antagonists & inhibitors
/ Biology
/ Biomedical and Life Sciences
/ Clinical Trials as Topic - methods
/ Drug Delivery Systems - methods
/ Drug Delivery Systems - trends
/ Excitatory Amino Acid Agents
/ Excitatory Amino Acid Agents - administration & dosage
/ Excitatory Amino Acid Agents - metabolism
/ Gait
/ Humans
/ Oligonucleotides, Antisense - administration & dosage
/ Oligonucleotides, Antisense - genetics
/ Oligonucleotides, Antisense - metabolism
/ Review
/ RNA Interference - drug effects
/ RNA Interference - physiology
/ SCA1
/ Spinocerebellar Ataxias - genetics
/ Spinocerebellar Ataxias - metabolism
